Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Evogene Price Performance

Shares of EVGN stock opened at $1.85 on Friday. The business’s fifty day moving average price is $1.69 and its 200 day moving average price is $3.21. The firm has a market capitalization of $9.93 million, a PE ratio of -0.41 and a beta of 1.30. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by hedge funds and other institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.